ClinicalTrials.gg
RecruitingNCT06846437Updated Mar 24, 2025

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

A Phase 3 interventional study of JSKN003 and Trastuzumab emtansine (T-DM1) in Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants, sponsored by Shanghai JMT-Bio Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited — 16 open to participants now, 18 under way, 10 of them phase 3. Breast Neoplasms · CSPC Pharmaceutical Group Limited.

Planned enrollment
14th of 26
228 · median 270
Started
2025
with 5 others
Phase 3
11 of 26
9 open now
Primary completion
2026-10
later than 7 of 17 live
Registered
16th of 26
by date

Among the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, this one is the 14th largest by planned enrollment, is one of 6 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 7 of the 17 other live ones, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.

Read the detailed description

This is a randomized, controlled, open-label, multicenter, phase 3 clinical study to compare the efficacy and safety of JSKN003 versus T-DM1 in unresectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane. Participants will be treated with JSKN003 at 6.3 mg/kg or trastuzumab emtansine at 3.6 mg/kg every 3 weeks (Q3W). Participants will continue to receive treatment until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.

03

Conditions studied

  • Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Voluntarily agree to participate in the study and sign the .
  • 2.Age≥18 years old.
  • 3.Patients with unresectable locally advanced or breast cancer confirmed by histology or cytology.
  • 4.Confirmed to be positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study center.
  • 5.Have received treatment regimen including trastuzumab (allowed marketed trastuzumab biosimilars) or inetetamab with radiologic or pathologic progression/ relapse during the advanced stage, during or adjuvant therapy, or within 12 months after treatment.
  • 6.Previously treated with taxanes.
  • 7.Had radiologic and/or pathologic progression or intolerance of the latest systemic anti-tumor therapy.
  • 8.At least one extracranial at baseline according to 1.1 criteria.
  • 9. PS of 0 - 1.
  • 10.Patients with adequate organ and bone marrow functions.
  • 11.Expected survival ≥ 3 months.
  • 12.Female and male patients of childbearing age agree to take adequate measures during and upon completion of the study for 7 months after the last dose of JSKN003 or T-DM1.

Exclusion criteria

Exclusion Criteria:

    1. Have previously been treated with an anti- ADC loaded with topoisomerase I inhibitors or medenosin derivative 1 (DM1) or have after receiving such therapy during or within 12 months after the /neo-adjuvant setting or in the advanced stage.
  • 2.History of any other malignant tumors within three years before randomization.
  • 3.With uncontrollable serous effusion within 14 days before randomization, which requires frequent drainage or medical intervention.
  • 4.Known to T-DM1or not suitable to receive JSKN003 or T-DM1 by investigator.
  • 5.Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 (refer to 5.0) or baseline (excluding grade 2 alopecia, hyperpigmentation, simple laboratory test abnormalities, and other toxicity for a non-safety risk by investigators).
  • 6.Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received palliative radiotherapy, endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization.
  • 7.Major organ surgery within 28 days before randomization.
  • 8.Untreated (including baseline findings) or unstable cerebral parenchymal , spinal cord metastasis or compression, and cancerous meningitis.
  • 9.The cumulative amount of previous exposure to anthracyclines has reached the pre-specified dosage.
  • 10.History of \< 40% during prior anti-HER2 drug therapy or symptomatic congestive heart failure (CHF).
  • 11.Serious or uncontrolled cardiovascular disease.
  • 12.History of (non-infectious) interstitial lung disease/pneumonitis requiring therapy or grade ≥3 interstitial lung disease/ pneumonitis during previous anti-tumor treatments.
  • 13.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization.
    1. Active or .
  • 15.History of immunodeficiency or antibody test positive at screening.
  • 16.Received a potent inhibitor of within 14 days prior to randomization or during study treatment.
  • 17.Pregnant or nursing females;
  • 18.Other reasons enrolled in this clinical trial as considered unsuitable by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    JSKN003

    Received JSKN003 as a sterile intravenous (IV) solution at a dose of 6.3 mg/kg every 3 weeks (Q3W).

    Drug: JSKN003

  • Active comparator
    T-DM1

    Received T-DM1 in accordance with the approved label.

    Drug: Trastuzumab emtansine (T-DM1)

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) by BIRC

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Progression-free survival (PFS) by investigator

    Time frame: Up to approximately 4 years

  2. Overall Survival (OS)

    Time frame: Up to approximately 4 years

  3. Objective Response Rate (ORR)

    Time frame: Up to approximately 4 years

  4. Disease Control Rate (DCR)

    Time frame: Up to approximately 4 years

  5. Duration of Response (DoR)

    Time frame: Up to approximately 4 years

  6. Incidence and severity of TEAE and SAE

    Time frame: From the signing of informed consent to the safety follow-up period or before starting a new anti-tumor therapy, whichever occurs first, assessed up to approximately 4 years.

  7. Cmax of JSKN003

    Time frame: Cycles 1, 2, 3, 4 (each cycle is 3 weeks), and every 4 cycles starting from Cycle 4; End of treatment and safety follow-up visit, for approximately 4 years

  8. AUC of JSKN003

    Time frame: Cycles 1, 2, 3, 4 (each cycle is 3 weeks), and every 4 cycles starting from Cycle 4; End of treatment and safety follow-up visit, for approximately 4 years

  9. Incidence of anti-drug antibodies (ADA) to JSKN003

    Time frame: Pre-dose for Cycles 1, 2, 3, 4 (each cycle is 3 weeks), and every 4 cycles starting from Cycle 4; End of treatment and safety follow-up visit, for approximately 4 years.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 19 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Feb 26, 2025
StartActual
Feb 18, 2025
Primary completionEst.
Oct 13, 2026
CompletionEst.
Dec 31, 2028
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06846437
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Feb 18, 2025
Primary completion
Oct 13, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 24, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587
Zhimin Shao, M.D.
Contact
:szm@163.com
+86 18017312288
Zhimin Shao, M.D. Organizational Affiliatio
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anbenitamab repodatecan

Start the discussion